Literature DB >> 25580412

Reliability of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in the nodal staging of colorectal cancer patients.

Hee Jung Yi1, Kyung Sook Hong1, Nara Moon1, Soon Sup Chung1, Ryung-Ah Lee1, Kwang Ho Kim1.   

Abstract

PURPOSE: Lymph-node metastasis is considered as critical prognostic factor in colorectal cancer. A preoperative evaluation of lymph-node metastasis can also help to determine the range of distant lymph node dissection. However, the reliability of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the detection of lymph-node metastasis is not fully known.
METHODS: The medical records of 433 patients diagnosed with colorectal cancer were reviewed retrospectively. FDG-PET/CT and CT were performed on all patients. Lymph nodes were classified into regional and distant lymph nodes according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition.
RESULTS: The patients included 231 males (53.3%) and 202 females (46.7%), with a mean age of 64.7 ± 19.0 years. For regional lymph nodes, the sensitivity of FDG-PET/CT was lower than that of CT (57.1% vs. 73.5%, P < 0.001). For distant lymph nodes, the sensitivity of FDG-PET/CT was higher than that of CT (64.7% vs. 52.9%, P = 0.012). The sensitivity of FDG-PET/CT for regional lymph nodes was higher in patients with larger primary tumors. The positivity of lymph-node metastasis for FDG-PET/CT was affected by carcinoembryonic antigen levels, tumor location, and cancer stage for regional lymph nodes and by age and cancer stage for distant lymph nodes (P < 0.05).
CONCLUSION: The sensitivity of FDG-PET/CT for regional lymph-node metastasis was not superior to that of CT. However, FDG-PET/CT provides helpful information for determining surgical plan especially in high risk patients group.

Entities:  

Keywords:  Colorectal neoplasms; Lymph node; Metastasis; Positron emission tomography

Year:  2014        PMID: 25580412      PMCID: PMC4286772          DOI: 10.3393/ac.2014.30.6.259

Source DB:  PubMed          Journal:  Ann Coloproctol        ISSN: 2287-9714


  16 in total

1.  GLUT1 expression in tissue and (18)F-FDG uptake.

Authors:  Norbert Avril
Journal:  J Nucl Med       Date:  2004-06       Impact factor: 10.057

2.  Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis.

Authors:  Shandra Bipat; Afina S Glas; Frederik J M Slors; Aeilko H Zwinderman; Patrick M M Bossuyt; Jaap Stoker
Journal:  Radiology       Date:  2004-07-23       Impact factor: 11.105

3.  Nodal staging of rectal cancer: high-resolution pelvic MRI versus ¹⁸F-FDGPET/CT.

Authors:  Dae Jung Kim; Joo Hee Kim; Young Hoon Ryu; Tae Joo Jeon; Jeong-Sik Yu; Jae-Joon Chung
Journal:  J Comput Assist Tomogr       Date:  2011 Sep-Oct       Impact factor: 1.826

4.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.

Authors:  H Abdel-Nabi; R J Doerr; D M Lamonica; V R Cronin; P J Galantowicz; G M Carbone; M B Spaulding
Journal:  Radiology       Date:  1998-03       Impact factor: 11.105

5.  The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.

Authors:  Hiroyuki Kato; Tatsuya Miyazaki; Masanobu Nakajima; Junko Takita; Hitoshi Kimura; Ahmad Faried; Makoto Sohda; Yasuyuki Fukai; Norihiro Masuda; Minoru Fukuchi; Ryokuhei Manda; Hitoshi Ojima; Katsuhiko Tsukada; Hiroyuki Kuwano; Noboru Oriuchi; Keigo Endo
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

Review 6.  Preoperative staging of rectal carcinoma.

Authors:  A G Heriot; A Grundy; D Kumar
Journal:  Br J Surg       Date:  1999-01       Impact factor: 6.939

7.  Classification of colorectal carcinomas with regional lymphatic metastases.

Authors:  P Hermanek; A Altendorf
Journal:  Pathol Res Pract       Date:  1981-12       Impact factor: 3.250

8.  Lumboaortic and iliac lymphadenectomy: what is the role today?

Authors:  A Leggeri; M Roseano; A Balani; A Turoldo
Journal:  Dis Colon Rectum       Date:  1994-02       Impact factor: 4.585

9.  Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.

Authors:  Iva Kantorová; Ludmila Lipská; Otakar Bêlohlávek; Vladimír Visokai; Miroslav Trubaĉ; Michaela Schneiderová
Journal:  J Nucl Med       Date:  2003-11       Impact factor: 10.057

10.  Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer.

Authors:  Ukihide Tateishi; Tetsuo Maeda; Tsuyoshi Morimoto; Mototaka Miyake; Yasuaki Arai; E Edmund Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-26       Impact factor: 9.236

View more
  4 in total

1.  Clinical evaluation of (18)F-fludeoxyglucose positron emission tomography/CT using point spread function reconstruction for nodal staging of colorectal cancer.

Authors:  Kazuya Kawashima; Kenichi Kato; Makiko Tomabechi; Mikaru Matsuo; Koki Otsuka; Kazuyuki Ishida; Ryuji Nakamura; Shigeru Ehara
Journal:  Br J Radiol       Date:  2016-05-05       Impact factor: 3.039

2.  Preoperative staging with positron emission tomography in patients with colorectal cancer.

Authors:  Young Wan Kim; Ik Yong Kim
Journal:  Ann Coloproctol       Date:  2014-12

Review 3.  Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging.

Authors:  Pier Paolo Mainenti; Arnaldo Stanzione; Salvatore Guarino; Valeria Romeo; Lorenzo Ugga; Federica Romano; Giovanni Storto; Simone Maurea; Arturo Brunetti
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

4.  Can Cross-Sectional Imaging Reliably Determine Pathological Staging of Right-Sided Colon Cancers and Select Patients for More Radical Surgery or Neo-Adjuvant Treatment?

Authors:  Florence Shekleton; Edward Courtney; Adrian Andreou; John Bunni
Journal:  Cureus       Date:  2022-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.